Expert Interview
A second look: Discussing the commercial prospects of Iomab-B from Actinium Pharmaceuticals in Acute Myeloid Leukemia
Ticker(s): ATNMInstitution: Yale
- Assistant Professor of Medicine (Hematology) at Yale.
- Focused on the care and research of patients with myeloid malignancies, particularly acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
- Participated in the K12 Calabresi Immuno-Oncology Training Program and has participated in several clinical trials aimed at improving the outcomes of patients with AML and MDS.
How many AML patients do you treat?
Added By: wilson_adminWhere do you see Iomab-B being used?
Added By: wilson_adminHow would you rate your enthusiasm over Iomab-B on a scale of 1-10?
Added By: wilson_adminDo you have experience using Iomab-B? If so, what is the process for radiation shielding?
Added By: wilson_adminBased on the current results, what % of your relapsed/refractory AML patients would you attemp Iomab-B
Added By: wilson_adminWhat are your thoughts on the phase 3 SIERRA trial data with respect to dCR, OS, and EFS?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
